News for Healthier Living

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models

This study finds BGB-A445, a non-ligand-competitive anti-OX40 antibody under clinical investigation, induces T cell activation, depletes regulatory T cells, shows robust antitumor efficacy in a mouse model, synergizes with anti-PD-1, and is superior to ligand-competitive ones, warranting further clinical study.

September 24, 2025


October 6 2025

October 5 2025

October 4 2025

October 3 2025

October 2 2025

October 1 2025

September 30 2025

September 29 2025

September 28 2025

September 27 2025

September 26 2025

September 25 2025

September 24 2025

September 23 2025

September 22 2025